Which beta‑blocker is safe to use in a pregnant woman with hyperthyroidism?

Metoprolol is the Safe Beta-Blocker for Pregnant Women with Hyperthyroidism

Metoprolol is specifically recommended by the Endocrine Society guidelines for symptomatic management of hyperthyroidism in pregnancy and should be used with obstetrical agreement 1. This represents the highest-quality guideline evidence available for beta-blocker selection in this clinical scenario.

Rationale for Metoprolol Selection

The 2012 Endocrine Society Clinical Practice Guidelines explicitly name metoprolol as the beta-blocker of choice for pregnant women with hyperthyroidism who require symptomatic control 1. This recommendation applies particularly to:

• Women with hyperemesis gravidarum and clinical thyrotoxicosis
• Patients who appear significantly thyrotoxic
• Those with serum total T3 values above the pregnancy reference range

The guideline specifies that beta-blockers provide symptomatic relief while antithyroid drug (ATD) therapy addresses the underlying disease, though many cases of gestational hyperthyroidism do not require ATD treatment at all 1.

Clinical Application Algorithm

When to use metoprolol in pregnant hyperthyroid patients:

1. Symptomatic thyrotoxicosis with tachycardia, tremor, or anxiety despite normal or mildly elevated thyroid hormones
2. Short-term bridging therapy while awaiting ATD effect (typically 2-4 weeks)
3. Hyperemesis gravidarum with clinical hyperthyroidism where immediate symptom control is needed
4. Thyroid storm preparation or acute severe thyrotoxicosis requiring rapid symptom control

Coordinate with obstetrics before initiating therapy, as the guidelines emphasize obstetrical agreement 1.

Important Caveats and Safety Considerations

While metoprolol is the guideline-recommended agent, beta-blockers should be used judiciously and for short durations in pregnancy. The evidence quality for this recommendation is rated as "poor" (USPSTF level B, evidence 2 QEEE) 1, reflecting limited high-quality data on beta-blocker safety in pregnancy.

Avoid prolonged beta-blocker use as it may theoretically cause:

• Fetal bradycardia
• Intrauterine growth restriction
• Neonatal hypoglycemia and bradycardia

Propranolol, while historically used and mentioned in older literature 2, 3, is not the guideline-recommended agent. Metoprolol's beta-1 selectivity offers theoretical advantages by minimizing beta-2 blockade effects on uterine tone and peripheral vasculature.

Integration with Primary Hyperthyroidism Treatment

Beta-blockers are adjunctive therapy only—they do not treat the underlying hyperthyroidism 1. For Graves' disease requiring definitive treatment:

• First trimester: Use propylthiouracil (PTU) to minimize teratogenic risk
• After 16 weeks: Consider switching to methimazole based on shared decision-making 4, 5
• Monitor closely: Maintain maternal free T4 at or just above the upper limit of normal

The goal is to use the lowest effective ATD dose while metoprolol provides temporary symptomatic relief during the initial treatment phase 5.

Practical Dosing Approach

Start with low-dose metoprolol (typically 25-50 mg twice daily) and titrate to heart rate control (target resting HR 80-90 bpm). Discontinue once euthyroidism is achieved with ATD therapy or once gestational thyrotoxicosis spontaneously resolves, which typically occurs by mid-pregnancy 1.